What Did We Learn From ESC 2017 COMPASS Trial Design COMPASS PantoprazoleBased Randomization COMPASS Outcomes COMPASS Primary Endpoints CV Death Stroke MI COMPASS Primary Components ID: 707300
Download Presentation The PPT/PDF document "Updates in Anticoagulation:" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Updates in Anticoagulation:What Did We Learn From ESC 2017?Slide2
COMPASS: Trial DesignSlide3
COMPASS: Pantoprazole-Based RandomizationSlide4
COMPASS: OutcomesSlide5
COMPASS: Primary EndpointsCV Death, Stroke, MISlide6
COMPASS: Primary ComponentsSlide7
COMPASS: Major BleedingSlide8
COMPASS: Net Clinical BenefitSlide9
COMPASS: SummarySlide10
RE-DUAL PCI: Study DesignMulticenter, Randomized, Open-Label PROBE Trial Slide11
RE-DUAL PCI: Primary EndpointISTH Major or CRNM Bleeding EventSlide12
RE-DUAL PCI: Rates of TIMI Major or Minor BleedingSlide13
RE-DUAL PCI: SummarySlide14
IMPACT-AF: Cluster Randomized TrialSlide15
IMPACT-AF: ResultsPersistence and New TreatmentSlide16
IMPACT AF: Clinical OutcomesSlide17
EMANATE: Study DesignSlide18
EMANATE: Stroke/SE OutcomesSlide19
XANTUS: A Worldwide ProgramSlide20
XANTUS: Efficacy and Safety in the Real WorldSlide21
REHEARSE-AFSlide22
AbbreviationsSlide23
Abbreviations (cont)